BRILIQUE RECEIVES A POSITIVE PRELIMINARY MEDICAL BENEFIT ASSESSMENT FOR THE MAJORITY OF ACS PATIENTS IN GERMANY AS PART OF NEW AMNOG REVIEW PROCESS

For immediate release: 4 October 2011 AstraZeneca today announced that the German reimbursement body, the Federal Joint Committee (G-BA), has published the Institute for Quality and Efficiency in Healthcare (IQWiG) preliminary assessment report regarding the medical benefit of BRILIQUE (ticagrelor). AstraZeneca is pleased with this preliminary assessment as we seek to help ensure ACS patients continue to have access to this innovative medicine in Germany. AMNOG (Arzneimittelmarkt-Neuordnungsgesetz) is a new law that became effective 1 January 2011 for the mandatory pricing and